- About Us
- Who We Serve
- Our Tissues & Products
- Contact Us
Edison, N.J. (March 7, 2018) – A unique system that has potential to improve outcomes from joint repair procedures continues to show positive clinical results. The Missouri Osteochondral Preservation System (MOPSSM) is a technology that more than doubles the storage life of allografts used for joint repairs. Created by the University of Missouri and available exclusively with tissue processed by MTF Biologics MOPSSM allografts have been shown to maintain more than twice the viable chondrocyte density for twice as long as standard of care (SOC) allografts.
“Not only does doubling the viable cell density and extending the life of an osteochondral allograft increase the time for a surgeon to schedule and perform the implantation, it has the potential to have a positive impact on clinical outcomes,” said Marc Long, PhD, Vice President of Research & Development at MTF Biologics. “MTF Biologics works hand in hand with clinicians and researchers like those at the University of Missouri to stay on the forefront of science and clinical research. We are honored to provide tissue for a remarkable innovation like MOPSSM as we continue to provide new clinical solutions for surgeons and their patients.”
A study, “Chondrocyte Viability at Time of Transplantation for Osteochondral Allografts Preserved by the Missouri Osteochondral Preservation System versus Standard Tissue Bank Protocol,” published in The Journal of Knee Surgery in October 2017 showed that MOPSSM allografts maintained 98.8 percent viable cell density at 40 to 55 days, compared to SOC allografts, which maintained only 22.9 percent viable cell density at 21 to 28 days after procurement. Importantly, all MOPSSM allografts evaluated in the study had higher than the desired minimum essential viability level of 70 percent, while only 27 percent of SOC grafts evaluated exceeded the desired level at the time of implantation. MOPSSM allografts also had a revision rate of only two percent, while the SOC allograft revision rate was 11.5 percent. Additionally, MOPSSM allografts had no early failures (6-24 months, mean = 12 months postop), compared to SOC allografts, which demonstrated an early failure rate of 3.8 percent in this study.
“We are very pleased with the overwhelmingly positive early results with the use of MOPSSM tissues and believe the data support the benefits of using grafts with high chondrocyte viability to optimize outcomes in patients,” said James L. Cook, DVM, PhD. “The partnership with MTF Biologics has allowed us to safely bring this technology to clinical use to help patients, surgeons, and donor families.”
The quality of tissue preserved with MOPSSM is important to its viability. MTF Biologics uses a unique aseptic processing method. This method ensures optimal tissue quality and helps to maintain the biomechanical integrity and biochemistry of every graft.To learn more about MOPSSM, visit MTF Biologics at booth 3151 at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting March 6-10, 2018, in New Orleans, La.